budesonide MMX

Phase 3Small molecule

Ferring

budesonide MMX is one of 45 small molecule programs targeting Microscopic Colitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Microscopic ColitisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Microscopic ColitisPhase 2

Active, not recruiting

Ulcerative ColitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Velsipity

Pfizer

Phase 3

11 2

Skyrizi

AbbVie

Phase 3

6 3

Jyseleca

Gilead

Phase 3

6 4

Tremfya

Johnson & Johnson

Phase 3

2 5

Mounjaro

Eli Lilly

Phase 3

1 6

Orencia

Bristol-Myers Squibb

Phase 3

1 7

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 8

Adtralza

LEO Pharma

Phase 3

1 9

Purinethol

SStason

Phase 3

1 10

Afimkibart

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Microscopic Colitis

NCT05915104

Clinical

Trials by Indication[1]

Ulcerative Colitis4 trials

Effectiveness of Cortiment® in Patients With Ulcerative Colitis

Completed· Ferring logo

Ferring··NCT02586259·378 enrolled

Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis

Unknown status·—·Phase 2/3·NCT05341401·100 enrolled

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

Completed·BBausch Health Americas, Inc.·Phase 3·NCT01532648·510 enrolled

Show 1 more trial

(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.

Completed·BBausch Health Americas, Inc.·Phase 3·NCT00801723·123 enrolled

Microscopic Colitis1 trial

Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis

Not yet recruiting·UUniversity of Calgary·Phase 2·NCT05915104·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for budesonide MMX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — budesonide MMX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for budesonide MMX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ferring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Ferring

budesonide MMX

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ulcerative Colitis4 trials

Microscopic Colitis1 trial

References

Drug Info

Quick Facts

Related News